X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PFIZER ALEMBIC PHARMA/
PFIZER
 
P/E (TTM) x 16.3 33.8 48.2% View Chart
P/BV x 3.6 5.4 65.7% View Chart
Dividend Yield % 1.1 0.6 170.2%  

Financials

 ALEMBIC PHARMA   PFIZER
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
PFIZER
Mar-18
ALEMBIC PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6642,365 28.1%   
Low Rs4121,625 25.4%   
Sales per share (Unadj.) Rs208.7430.3 48.5%  
Earnings per share (Unadj.) Rs31.078.7 39.4%  
Cash flow per share (Unadj.) Rs37.193.2 39.8%  
Dividends per share (Unadj.) Rs5.5020.00 27.5%  
Dividend yield (eoy) %1.01.0 101.9%  
Book value per share (Unadj.) Rs144.2586.5 24.6%  
Shares outstanding (eoy) m188.5245.75 412.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.6 55.6%   
Avg P/E ratio x17.425.3 68.5%  
P/CF ratio (eoy) x14.521.4 67.7%  
Price / Book Value ratio x3.73.4 109.7%  
Dividend payout %17.725.4 69.8%   
Avg Mkt Cap Rs m101,46191,271 111.2%   
No. of employees `000NA2.6 0.0%   
Total wages/salary Rs m7,4673,143 237.6%   
Avg. sales/employee Rs ThNM7,484.8-  
Avg. wages/employee Rs ThNM1,195.0-  
Avg. net profit/employee Rs ThNM1,369.1-  
INCOME DATA
Net Sales Rs m39,34719,685 199.9%  
Other income Rs m941,143 8.2%   
Total revenues Rs m39,44120,828 189.4%   
Gross profit Rs m8,7365,003 174.6%  
Depreciation Rs m1,152663 173.9%   
Interest Rs m1844 4,383.3%   
Profit before tax Rs m7,4935,479 136.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5681,878 83.4%   
Profit after tax Rs m5,8443,601 162.3%  
Gross profit margin %22.225.4 87.4%  
Effective tax rate %20.934.3 61.0%   
Net profit margin %14.918.3 81.2%  
BALANCE SHEET DATA
Current assets Rs m19,57724,167 81.0%   
Current liabilities Rs m14,8969,544 156.1%   
Net working cap to sales %11.974.3 16.0%  
Current ratio x1.32.5 51.9%  
Inventory Days Days9055 162.9%  
Debtors Days Days4529 158.0%  
Net fixed assets Rs m27,0979,514 284.8%   
Share capital Rs m377458 82.4%   
"Free" reserves Rs m26,81126,375 101.7%   
Net worth Rs m27,18826,832 101.3%   
Long term debt Rs m4,99325 19,972.0%   
Total assets Rs m47,77836,900 129.5%  
Interest coverage x41.71,305.5 3.2%   
Debt to equity ratio x0.20 19,710.3%  
Sales to assets ratio x0.80.5 154.4%   
Return on assets %12.69.8 129.1%  
Return on equity %21.513.4 160.2%  
Return on capital %23.620.4 115.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45322 86,842.4%   
Fx outflow Rs m6,0651,489 407.4%   
Net fx Rs m13,388-1,466 -913.0%   
CASH FLOW
From Operations Rs m8,1203,318 244.7%  
From Investments Rs m-7,556-2,383 317.1%  
From Financial Activity Rs m590-1,104 -53.5%  
Net Cashflow Rs m1,153-169 -684.5%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 2.9 7.5 38.7%  
FIIs % 9.1 4.9 185.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.7 58.6%  
Shareholders   49,328 85,207 57.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 305 Points Lower; FMCG and Finance Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 22, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - FULFORD INDIA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS